Vyome Therapeutics: Undervalued Buy on De-Risked VT-1953 Program and Pivotal Phase 3 Catalyst in a >$2B Orphan Market
at www.tipranks.com (Thu, 23-Apr 1:35 PM)
Independent Analyst Values Vyome’s VT-1953 at Nearly $1 Billion Post-Phase 3—Peak U.S. Sales Could Reach $600 Million
Market Chameleon (Tue, 27-Jan 9:52 AM)
Independent Analysis Sees Vyome’s VT-1953 Asset Value Approaching $1 Billion After Phase 3 Study
Market Chameleon (Tue, 27-Jan 8:20 AM)
